Silvia Tempia Valenta, Michele Stecchi, Federica Perazza, Chiara Nuccitelli, Nicola Villanova, Loris Pironi, Anna Rita Atti, Maria Letizia Petroni
INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS: A clinical audit was carried out on a cohort of 54 adults with obesity treated with liraglutide 3.0 mg. We retrospectively analyzed the connection between psychiatric symptoms assessed through the State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), and Binge Eating Scale (BES)...
November 28, 2023: Eating and Weight Disorders: EWD